Literature DB >> 23137921

Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter?

Stacy A Voils1, Brian Baird.   

Abstract

INTRODUCTION: Prothrombin complex concentrates are used for rapid reversal of vitamin K antagonists in patients with bleeding or those requiring surgery or invasive procedures. Current guidelines suggest 4-factor products are preferred over 3-factor prothrombin complex concentrates.
MATERIALS AND METHODS: We performed a systematic review comparing the effectiveness of 3-factor to 4-factor prothrombin complex concentrates in normalizing the international normalized ratio to ≤ 1.5 in patients with acquired coagulopathy due to vitamin K antagonist use. Studies reporting administration of prothrombin complex concentrates for emergent reversal of vitamin K antagonists that included results of baseline prothrombin time/international normalized ratio and follow-up testing within 60 minutes of prothrombin complex concentrates administration were included.
RESULTS: A total of 18 studies were included representing 654 patients. The most common indications for prothrombin complex concentrate were intracerebral hemorrhage, urgent surgery or invasive procedure, and gastrointestinal bleeding. Baseline international normalized ratio values ranged from 3.3-5.1 in the 3-factor group and from 2.3 to greater than 20 in the 4-factor group. The international normalized ratio repeated within one hour of prothrombin complex concentrates administration ranged from 1.2-1.9 in the 3-factor group and 1.0-1.9 in the 4-factor group. International normalized ratio decreased to ≤ 1.5 within one hour after prothrombin complex concentrates administration in 6 of 9 studies in the 3-factor group, and 12 of 13 studies in the 4-factor group.
CONCLUSION: More reliable correction of the international normalized ratio was seen with 4-factor compared to 3-factor prothrombin complex concentrates which may have clinical implications since 4-factor products are unavailable in some countries.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23137921     DOI: 10.1016/j.thromres.2012.10.001

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  21 in total

1.  Three-Factor Versus Four-Factor Prothrombin Complex Concentrate for the Emergent Management of Warfarin-Associated Intracranial Hemorrhage.

Authors:  Daniel Fischer; Jeffrey Sorensen; Gabriel V Fontaine
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

2.  Interrupting anticoagulation in patients with nonvalvular atrial fibrillation.

Authors:  Scott W Yates
Journal:  P T       Date:  2014-12

3.  Prothrombin complex concentrate.

Authors:  Dennis J Cada; Terri L Levien; Danial E Baker
Journal:  Hosp Pharm       Date:  2013-12

Review 4.  Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.

Authors:  Kamrouz Ghadimi; Jerrold H Levy; Ian J Welsby
Journal:  Anesth Analg       Date:  2016-05       Impact factor: 5.108

5.  3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in Severe Bleeding: A Multicenter, Retrospective, Propensity-Matched Pilot Study.

Authors:  G Morgan Jones; Michael J Erdman; Keaton S Smetana; Kerry M Mohrien; Joseph E Vandigo; Lucas Elijovich
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

Review 6.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.

Authors:  Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

7.  Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage.

Authors:  Jennifer A Frontera; Errol Gordon; Victor Zach; Maximo Jovine; Ken Uchino; Muhammad S Hussain; Louis Aledort
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

8.  Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel.

Authors:  Christopher W Baugh; Michael Levine; David Cornutt; Jason W Wilson; Richard Kwun; Charles E Mahan; Charles V Pollack; Evie G Marcolini; Truman J Milling; W Frank Peacock; Rachel P Rosovsky; Fred Wu; Ravi Sarode; Alex C Spyropoulos; Todd C Villines; Timothy D Woods; John McManus; James Williams
Journal:  Ann Emerg Med       Date:  2019-11-13       Impact factor: 5.721

Review 9.  Reversing vitamin K antagonists: making the old new again.

Authors:  Sabine Eichinger
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 10.  Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies.

Authors:  Arne Lauer; Waltraud Pfeilschifter; Chris B Schaffer; Eng H Lo; Christian Foerch
Journal:  Lancet Neurol       Date:  2013-03-18       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.